archive-com.com » COM » H » HBMPARTNERS.COM

Total: 38

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • HBM Partners AG - Current Private Portfolio
    PAH and lymphedema Ellipse Technologies USA Adjustable orthopedic implants Company Website www ellipse tech com HBM contact Dr Thomas Thaler Company status private Ellipse Technologies designs develops and commercializes non invasively adjustable remote controlled implants for a broad spectrum of spinal and othopedic applications Ellipse products aid to restore proper anatomic position and aligemnt of the spine and correct limb length discrepancies Gynesonics USA Women s Health Company Website www gynesonics com HBM contact Dr Chandra Leo Company status private Gynesonics focuses on the incision less therapy of symptomatic uterine fibroids the most common benign tumors in women Gynesonics has developed VizAblate a transcervical ultrasound guided ablation system which has a CE Mark in the European Union i Optics Netherlands Diagnostics ophthalmology Company Website www i optics com HBM contact Dr Chandra Leo Company status private he EasyScan scanning laser ophthalmoscope offers a dilation free 3 minute retinal exam for the early detection of diseases such as diabetic retinopathy The Cassini color LED topographer provides a highly precise 3 dimensional map of the cornea supporting e g cataract surgery planning and determination of IOL implants Iconic Therapeutics Drug development ophthalmology Company Website www iconictherapeutics com HBM contact Dr Priyanka Belawat Dr Matthias Fehr Company status private Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines for serious diseases The company s expertise in the role of Tissue Factor TF in angiogenesis inflammation and metastasis has allowed us to develop a unique therapeutic approach to retinal disease and cancer Interventional Spine USA Percutaneous spine implants Company Website www i spineinc com HBM contact Dr Thomas Thaler Company status private Interventional Spine designs develops and markets patented implantable devices for the spine that can be deployed via percutaneous techniques Kolltan Pharmaceuticals USA Drug development oncology Company Website www kolltan com HBM contact Axel Bolte MBA Company status private Kolltan Pharmaceuticals Inc is developing novel monoclonal antibody drugs targeting receptor tyrosine kinases RTKs Lipid Therapeutics Drug development inflammation Company Website lipid therapeutics com HBM contact Dr Alexander Asam Company status private Lipid Therapeutics GmbH is developing novel therapies for inflammatory diseases of the digestive system The company s current focus is to develop LT 02 a delayed release of Phosphatidylcholine for the treatment of Ulcerative colitis LT 02 is currently in PhIII clinical development MiCardia Corporation USA Heart valve implants Company Website www micardia com HBM contact Dr Thomas Thaler Company status private MiCardia is marketing its enCorSQ Mitral Valve Repair System in the Europe The enCorSQ device allows the surgeon to address any recurrent MR or coaptation correction real time off pump on a beating heart days or months after the surgical implant Nabriva Austria Drug development antibacterials Company Website www nabriva com HBM contact Axel Bolte MBA Company status public Nabriva Therapeutics is developing pleuromutilin antibiotics a new class of antibacterial compounds for the treatment of serious infections in humans caused by multi drug resistant pathogens ObsEva Women s Health Company Website www obseva

    Original URL path: http://www.hbmpartners.com/en/portfolio/current-private-portfolio.php (2016-04-25)
    Open archived version from archive


  • HBM Partners AG - HBM Industry Reports
    2003 2015 Excel Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February

    Original URL path: http://www.hbmpartners.com/en/industry-reports/new-drug-approval-report.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Volltextsuche
    of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016 with Morningstar HBM Global Biotechnology Fund is A rated by Citywire for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016 FINMA

    Original URL path: http://www.hbmpartners.com/en/suche/index.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Partners Ltd
    as sole arbitrator chairman party appointed arbitrator and counsel and in certain complex commercial banking litigations He regularly advises on contractual and corporate law He has been a member of the Arbitration Committee of the Geneva Chamber of Commerce and Industry and of the National Arbitration Committee Swiss Rules of International Arbitration and is lecturer within the framework of the executive education program on Compliance Management organized by the University of Geneva Stanislas Poniatowski Member of the Board of Directors Mr Poniatowski is on the Investment Committee of Royalty Pharma the global leader in holding and acquiring royalty interests of leading biopharmaceutical products He currently serves on various boards of Quilvest S A Luxembourg entities and is notably Chairman of the Board of Quilvest and Partners Mr Poniatowski is also a board member of International Advisory Services Terold S A Luxembourg Grupo Peñaflor Argentina Tiendas BBB Mexico Chairman of StarTeq Holding Luxembourg and of a number of investment companies He is also Chairman of the non profit Fondation ARPE in Switzerland Mr Poniatowski was a senior banker with Lazard Frères in the United States and in Europe from 1976 through 2003 where he was most recently a Managing Director While at Lazard Mr Poniatowski worked in the mergers and acquisitions and corporate advisory during which time he was involved with a number of cross border assignments and transactions in Europe the United States and Latin America Mr Poniatowski has a degree in Financial Management from Ecole des Cadres EDC in Paris Neuilly France Dr Andreas Wicki Management CEO Successful healthcare entrepreneur and investor with over 15 years of experience in the pharmaceutical and biotechnology industries He was co owner and CEO of ANAWA Holding AG a healthcare analytical services company MSc and PhD in chemistry and biochemistry from the University

    Original URL path: http://www.hbmpartners.com/en/unternehmen/organisation/board-overview.php?navid=1266092578736 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Credits
    and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016 with Morningstar HBM Global Biotechnology Fund is A rated by Citywire for its

    Original URL path: http://www.hbmpartners.com/en/impressum/index.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Rechtliche Hinweise
    site may contain third party information and links to third parties which have been selected carefully at setup Such third party information does not necessarily represent the opinion of HBM Partners and links to third party sites are provided for navigational convenience only HBM Partners does not express any opinion on the content of such third party information or sites and expressly disclaims any liability or responsibility for all third party information and the use of it No offer and no solicitation All data on this website are without obligation and non binding They serve merely informational purposes and do not represent any sort of decision making criteria for any questions in particular for investment decisions The information provided on this website does not constitute an offer advertisement invitation for action advice or solicitation for the purchase or disposal of trading or any transaction in any security or any other investment instrument Investors must not rely on this information for investment decisions Past performance and historical data are not indicative of future performance Privacy HBM Partners Investments or mandated third parties may monitor traffic on and to this website and collect such traffic data These data as well as information which is sent to this website are not disclosed to third parties However they are not treated confidential and the sender renounces all copyrights If you request to receive our news items this request is valid until you withdraw it in writing Copyright The website of HBM Partners and the data presented including texts pictures and layout are if not indicated otherwise the property of HBM Partners and protected by copyright laws The use of this website shall not constitute any right to use the electronically transmitted data otherwise than for personal informational purposes in particular not for commercial use

    Original URL path: http://www.hbmpartners.com/en/impressum/rechtliche-hinweise.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Partners Ltd
    as sole arbitrator chairman party appointed arbitrator and counsel and in certain complex commercial banking litigations He regularly advises on contractual and corporate law He has been a member of the Arbitration Committee of the Geneva Chamber of Commerce and Industry and of the National Arbitration Committee Swiss Rules of International Arbitration and is lecturer within the framework of the executive education program on Compliance Management organized by the University of Geneva Stanislas Poniatowski Member of the Board of Directors Mr Poniatowski is on the Investment Committee of Royalty Pharma the global leader in holding and acquiring royalty interests of leading biopharmaceutical products He currently serves on various boards of Quilvest S A Luxembourg entities and is notably Chairman of the Board of Quilvest and Partners Mr Poniatowski is also a board member of International Advisory Services Terold S A Luxembourg Grupo Peñaflor Argentina Tiendas BBB Mexico Chairman of StarTeq Holding Luxembourg and of a number of investment companies He is also Chairman of the non profit Fondation ARPE in Switzerland Mr Poniatowski was a senior banker with Lazard Frères in the United States and in Europe from 1976 through 2003 where he was most recently a Managing Director While at Lazard Mr Poniatowski worked in the mergers and acquisitions and corporate advisory during which time he was involved with a number of cross border assignments and transactions in Europe the United States and Latin America Mr Poniatowski has a degree in Financial Management from Ecole des Cadres EDC in Paris Neuilly France Dr Andreas Wicki Management CEO Successful healthcare entrepreneur and investor with over 15 years of experience in the pharmaceutical and biotechnology industries He was co owner and CEO of ANAWA Holding AG a healthcare analytical services company MSc and PhD in chemistry and biochemistry from the University

    Original URL path: http://www.hbmpartners.com/en/unternehmen/organisation/board-overview.php?navid=809942809942 (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Partners Ltd
    Switzerland a generics company as project and business development manager MD from the Medical School of the University of Zurich Member of the Board of Directors of Asthmatx Pelikan Technologies and Broncus Dr Matthias Fehr CFA Private Equity Over fifteen years of experience in private and public equity investment management and research Former senior sell side analyst at Lombard Odier for the biotech and medical technology industries researcher in asymmetric synthesis at the Swiss Federal Institute of Technology in collaboration with Roche Honoured MSc and PhD in chemistry from the Swiss Federal Institute of Technology ETH Zurich Dr Ulrich Geilinger Management Head Private Equity Over 20 years of venture capital experience at Innoventure Credit Suisse Apax and Vontobel former advisory board member of leading European private equity funds including Apax Atlas and others Studied natural sciences and industrial engineering at the Swiss Federal Institute of Technology ETH Zurich and completed his studies with a PhD Former board member EVCA and former president of SECA Board member of Westmed Reha Technology and Medimpulse Biocontrol Nina Good Compliance Over ten years of experience in the financial industry including both Investment Banking as well as Private Wealth Management for UBS Several years experience covering Compliance for Schroder Investment Management Switzerland a fund management company asset manager and Swiss representative of foreign funds Holds a Bachelor of Science ZFH in Business Administration from HWZ University of Applied Sciences in Business Administration Zurich a DAS in Compliance Management from Hochschule Luzern FHZ Lucerne University of Applied Sciences as well as a CFA Claritas Diploma Dr Dominique Küttel CFA Business Development Distribution Fifteen years of experience in banking and asset management at UBS and Gottex Fund Management in Switzerland and in England His activities included product structuring offering tailor made solutions in the alternative area leading European sales as well as managing several sales and product teams He has two Masters and a Doctorate in Economics with specialization in econometrics and financial markets at the universities of Basel Lausanne HEC Geneva HEI and the Study Center Gerzensee Michael Jasulavic MSc Public Equity Over 10 years of experience in healthcare investment research strategy and trade execution Former biotechnology analyst at Traxis Partners Sivik Global Healthcare and Jefferies Asset Management MS in Medical Science from the MCP Hahnemann School of Medicine Thomas Heimann MSc Risk Management Several years experience in Investment Research Analysis at HBM Partners and 4 years experience at Luzerner Kantonalbank as assistant to customer relationship manager within the mortgages loans and real estate financing department Holds a Master and Bachelor of Science in Banking Finance from the Lucerne University of Applied Sciences and Arts Various publications together with Ernst Young HBM Partners and SECA Swiss Private Equity Corporate Finance Association with topics on healthcare investing valuation and financing Dr Chandra Leo MBA Private Equity Over fifteen years of experience in private equity clinical practice and biomedical research Current board member at CardiacAssist Delenex Therapeutics Gynesonics and i Optics board observer at Symbiomix Previously served as

    Original URL path: http://www.hbmpartners.com/en/unternehmen/organisation/investitionsberater-europa.php (2016-04-25)
    Open archived version from archive



  •